| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | NILR; CD360 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL21R |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL21R抗体的3-4篇文献的简要概括(内容为模拟虚构，仅供参考)：
1. **文献名称**: *"Targeting IL-21 Receptor Signaling Attenuates Autoimmune Disease in Mouse Models"*
**作者**: Gurney, A.L. et al.
**摘要**: 研究通过阻断IL21R抗体在小鼠模型中抑制Th17细胞活化和炎症因子释放，显著减轻类风湿性关节炎和炎症性肠病症状，表明IL21R是治疗自身免疫疾病的重要靶点。
2. **文献名称**: *"IL-21 Receptor-Specific Antibody Enhances Antitumor Immunity by Promoting CD8+ T Cell Activity"*
**作者**: Leonard, W.J. et al.
**摘要**: 开发一种人源化IL21R单克隆抗体，通过增强CD8+ T细胞的增殖和细胞毒性，与PD-1抑制剂联用显著抑制黑色素瘤小鼠的肿瘤生长，提出其在联合免疫治疗中的潜力。
3. **文献名称**: *"IL-21R Deficiency Alters B Cell Homeostasis and Antibody Responses"*
**作者**: Parrish-Novak, J. et al.
**摘要**: 通过IL21R基因敲除小鼠模型，揭示IL21R信号缺失导致B细胞分化异常及抗体类别转换缺陷，强调了IL21R在体液免疫调控中的关键作用。
4. **文献名称**: *"A Phase I Clinical Trial of Anti-IL21R Antibody in Patients with Psoriasis"*
**作者**: Fouser, L.A. et al.
**摘要**: 首次报道抗IL21R抗体(ABT-123)在银屑病患者中的I期临床试验结果，证明其安全性，并观察到患者皮肤病变评分显著降低，提示临床治疗潜力。
注：以上文献信息为示例性虚构，实际研究需通过PubMed或学术数据库检索。
The interleukin-21 receptor (IL21R) is a cell surface protein belonging to the type I cytokine receptor family, which pairs with the common γ-chain (γc) to form a functional receptor complex. It plays a critical role in modulating immune responses by binding its ligand, IL-21. a pleiotropic cytokine produced predominantly by CD4+ T follicular helper (Tfh) cells and natural killer T (NKT) cells. IL21R signaling influences the activation, proliferation, and differentiation of various immune cells, including B cells, T cells, NK cells, and dendritic cells. Dysregulation of the IL-21/IL21R axis is implicated in autoimmune diseases (e.g., rheumatoid arthritis, lupus), inflammatory disorders, and cancers, making it a therapeutic target.
IL21R antibodies are engineered to either block or modulate this pathway. Antagonistic antibodies inhibit IL-21 binding or receptor dimerization, suppressing downstream JAK/STAT, MAPK, and PI3K signaling pathways. This approach is explored in autoimmune conditions to curb pathogenic immune activity. Conversely, agonistic antibodies may enhance IL21R signaling to boost anti-tumor immunity or vaccine efficacy. Clinical development includes monoclonal antibodies (e.g., anti-IL21R mAbs) and fusion proteins, often optimized for specificity and reduced immunogenicity. Challenges include balancing efficacy with potential immunosuppressive risks and optimizing tissue targeting. Preclinical and early clinical trials demonstrate promise in conditions like inflammatory bowel disease and B-cell malignancies, highlighting IL21R's dual role as a checkpoint in immune homeostasis and disease.
×
